Optimization of capital structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces the intention
of launching a voluntary share redemption program.

“The successful market introduction of simeprevir has led to a very strong cash
position and profitability for Medivir within a short time frame. Based on our
strategy update and plan, which will be presented today at the Capital Markets
Meeting, the company has analysed its capital structure and come to the
conclusion that there is room for a larger capital distribution to the
shareholders”, says Niklas Prager, CEO of Medivir.

The Board has decided to recommend a two-step approach:

  · Short-term, a one-off distribution of 625 MSEK (20 SEK/share) through a
voluntary redemption of shares for all shareholders. The Board expects to
convene an Extraordinary General Meeting in the next few days, proposing the
full resolutions to be passed for the purpose of the redemption. The
Extraordinary General Meeting is expected to be held on 20 November 2014. The
redemption procedure will run into Q1 2015.
  · Seek mandate for a share buy-back programme at the Annual General Meeting in
May 2015.

“Going forward, Medivir has the intention to work continuously with optimising
the capital structure, based on an assessment of financial position and
investment opportunities”, adds Niklas Prager, CEO of Medivir

The Capital Market Meeting will be held today at 14.00 CET at the Conference
Center Nio Rum, and will also be available on-line via Webcast, accessible
through Medivir’s website www.medivir.com.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 13.45 CET on 16 October 2014.

About Medivir
Medivir is an emerging and profitable research‐based pharmaceutical company with
an established marketing and sales organisation in the Nordic region with a
broad portfolio of prescription pharmaceuticals.
Medivir receives royalties from Johnson & Johnson on the global sales of the
hepatitis C pharmaceutical, Olysio®. In addition, revenues for sales of Olysio
in the Nordic region are generated through the company’s own sales and marketing
organisation. Medivir’s research and development portfolio of pharmaceuticals is
based on the company’s expertise within protease inhibitor design and
nucleoside/nucleotide science. The company’s research and development focus is
within infectious diseases and oncology and the on-going clinical projects in
osteoarthritis and neuropathic pain.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.